MicroRNA‑25‑3p regulates human nucleus pulposus cell proliferation and apoptosis in intervertebral disc degeneration by targeting Bim.

Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE

Original Publication: Athens, Greece : D. A. Spandidos

Bcl-2-Like Protein 11/*genetics ; Intervertebral Disc Degeneration/*genetics ; MicroRNAs/*genetics ; Nucleus Pulposus/*cytology; Animals ; Apoptosis ; Bcl-2-Like Protein 11/metabolism ; Cell Proliferation ; Disease Models, Animal ; Gene Expression Regulation ; Humans ; Intervertebral Disc Degeneration/metabolism ; Male ; Nucleus Pulposus/metabolism ; Rats

Intervertebral disc degeneration (IDD) is a degenerative disease of the spine originating from the intervertebral disc. MicroRNAs (miRNAs or miRs) are a group of endogenous small non‑coding RNAs that act on target genes and play a critical role in numerous biological processes. However, the underlying mechanism of miR‑25‑3p in IDD remains unclear. Therefore, the present study aimed to explore the role of miR‑25‑3p in the pathogenesis of IDD. The results demonstrated that miR‑25‑3p was downregulated in rat degenerative nucleus pulposus (NP) cells and that Bcl‑2 interacting mediator of cell death (Bim) was a direct target of miR‑25‑3p. Next, to investigate the effect of miR‑25‑3p on normal NP cell proliferation and apoptosis, NP cells were transfected with an miR‑25‑3p inhibitor, a negative control of miR‑25‑3p inhibitor, miR‑25‑3p inhibitor + control‑small interference RNA (siRNA) or miR‑25‑3p inhibitor + Bim‑siRNA for 48 h and cell proliferation and apoptosis were then analyzed. The results demonstrated that the miR‑25‑3p inhibitor could decrease NP cell proliferation and induce cell apoptosis, and these effects were reversed by Bim‑siRNA. In addition, an in vitro cell model of IDD was established by subjecting NP cells to 10 ng/ml interleukin (IL)‑1β for 24 h. Further experiments suggested that IL‑1β treatment induced a reduction in NP cell proliferation and an increase in cell apoptosis, which were prevented by the miR‑25‑3p mimic. All the effects of miR‑25‑3p mimic on IL‑1β‑treated NP cells were significantly reversed by Bim upregulation. These findings suggested that miR‑25‑3p may be a novel therapeutic target for IDD prevention.

J Pathol. 2011 Oct;225(2):232-42. (PMID: 21706480)
PLoS One. 2013 Dec 20;8(12):e83080. (PMID: 24376640)
Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3088-3097. (PMID: 28742197)
PLoS One. 2013 Sep 25;8(9):e75251. (PMID: 24086481)
Curr Opin Plant Biol. 2004 Apr;7(2):120-5. (PMID: 15003210)
Cells. 2019 Nov 18;8(11):. (PMID: 31752117)
Ann Rheum Dis. 2018 May;77(5):770-779. (PMID: 29343508)
Osteoarthritis Cartilage. 2015 Jul;23(7):1057-70. (PMID: 25827971)
Spine (Phila Pa 1976). 2009 Dec 1;34(25):E918-22. (PMID: 19940721)
Cancer Lett. 2018 Aug 1;428:90-103. (PMID: 29680223)
Bone. 2006 Nov;39(5):1073-1079. (PMID: 16829221)
Physiologist. 1996 Aug;39(4):199, 208-11. (PMID: 8854724)
Asian Pac J Trop Med. 2013 Sep;6(9):743-7. (PMID: 23827155)
Int J Mol Med. 2018 Feb;41(2):749-756. (PMID: 29207013)
Nature. 2002 Feb 21;415(6874):922-6. (PMID: 11859372)
Am J Transl Res. 2017 Nov 15;9(11):4925-4935. (PMID: 29218090)
Exp Biol Med (Maywood). 2015 Apr;240(4):411-7. (PMID: 25304312)
J Neurochem. 2008 Jun 1;105(6):2091-7. (PMID: 18266926)
Spine (Phila Pa 1976). 1996 Dec 15;21(24):2820-5. (PMID: 9112705)
Southeast Asian J Trop Med Public Health. 2014 Sep;45(5):1107-13. (PMID: 25417512)
Drug Discov Today. 2017 Feb;22(2):424-432. (PMID: 27815139)
Braz J Med Biol Res. 2013 Mar;46(3):235-44. (PMID: 23532265)
Biochem Soc Trans. 2018 Feb 19;46(1):11-21. (PMID: 29196609)
J Bone Miner Res. 2016 Apr;31(4):900-9. (PMID: 26587789)
Int J Mol Sci. 2014 Mar 05;15(3):4007-18. (PMID: 24603539)
Aerosp Med Hum Perform. 2017 Dec 1;88(12):1123-1128. (PMID: 29157342)
Nucleic Acids Res. 2007;35(17):5944-53. (PMID: 17726050)
Joint Bone Spine. 2008 Jul;75(4):388-96. (PMID: 18485784)
Health Policy. 2008 Dec;88(2-3):166-75. (PMID: 18455259)
Free Radic Biol Med. 2018 May 20;120:368-379. (PMID: 29649568)
Oncogene. 2009 Apr 23;28(16):1864-74. (PMID: 19305426)
Immunity. 2009 Jan 16;30(1):56-66. (PMID: 19119023)
Arthritis Rheum. 2009 Sep;60(9):2723-30. (PMID: 19714579)
Genes Dev. 2019 Dec 1;33(23-24):1673-1687. (PMID: 31699777)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Annu Rev Med. 2009;60:167-79. (PMID: 19630570)
Expert Opin Pharmacother. 2009 Nov;10(16):2581-92. (PMID: 19874246)
J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:3-9. (PMID: 16595435)
J Cell Biol. 2010 Apr 5;189(1):83-94. (PMID: 20351066)
Aging (Albany NY). 2016 Sep 29;8(9):1834-1835. (PMID: 27688082)
Osteoarthritis Cartilage. 2011 Aug;19(8):1011-8. (PMID: 21549847)
Cell Prolif. 2019 Sep;52(5):e12664. (PMID: 31343104)
Int J Oncol. 2007 Feb;30(2):313-8. (PMID: 17203211)

0 (BCL2L11 protein, human)
0 (Bcl-2-Like Protein 11)
0 (MIRN25 microRNA, human)
0 (MicroRNAs)

Date Created: 20200909 Date Completed: 20210426 Latest Revision: 20210426

20250114

PMC7533515

10.3892/mmr.2020.11483

32901887